← Back to Screener
Neurogene, Inc. Common Stock (NGNE)
Price$26.49
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)17.74%
Price vs S&P 500 (4W)-13.93%
VGM Score66.46
Market Capitalization$418.59M
All Metrics
Book Value / Share (Quarterly)$15.23
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-5.33
Price vs S&P 500 (YTD)20.43%
EPS (TTM)$-3.16
10-Day Avg Trading Volume0.09M
EPS Excl Extra (TTM)$-3.16
EPS (Annual)$-4.24
ROI (Annual)-34.11%
Cash / Share (Quarterly)$15.57
ROA (Last FY)-31.31%
EBITD / Share (TTM)$-3.50
ROE (5Y Avg)-36.27%
Cash Flow / Share (Annual)$-5.06
P/B Ratio1.76x
P/B Ratio (Quarterly)1.32x
Net Income / Employee (Annual)$-689,700
Net Interest Coverage (TTM)-51.05x
ROA (TTM)-23.25%
EPS Incl Extra (Annual)$-4.24
Current Ratio (Annual)16.56x
Quick Ratio (Quarterly)12.92x
3-Month Avg Trading Volume0.16M
52-Week Price Return15.58%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)452.53x
Asset Turnover (Annual)0.00x
52-Week High$37.27
EPS Excl Extra (Annual)$-4.24
CapEx CAGR (5Y)-11.82%
26-Week Price Return25.66%
Quick Ratio (Annual)16.44x
13-Week Price Return19.70%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)13.08x
Enterprise Value$294.44M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-8123.68%
Cash / Share (Annual)$17.37
3-Month Return Std Dev73.45%
Net Income / Employee (TTM)$-516,800
ROE (Last FY)-34.11%
Net Interest Coverage (Annual)-533.55x
EPS Basic Excl Extra (Annual)$-4.24
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.16
Receivables Turnover (Annual)0.00x
ROI (TTM)-25.27%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-8.79%
Year-to-Date Return28.59%
5-Day Price Return-3.81%
EPS Normalized (Annual)$-4.24
ROA (5Y Avg)-31.36%
Net Profit Margin (Annual)-8123.68%
Month-to-Date Return-6.53%
EBITD / Share (Annual)$-4.70
Operating Margin (Annual)-8930.27%
LT Debt / Equity (Annual)0.25x
ROI (5Y Avg)-36.21%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-3.16
P/B Ratio (Annual)1.20x
Book Value / Share (Annual)$17.10
Price vs S&P 500 (13W)11.45%
Beta1.73x
Revenue / Share (TTM)$0.00
ROE (TTM)-25.27%
52-Week Low$14.65
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-1.39est. -1.32
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.29
4.29
4.33
4.33
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NGNENeurogene, Inc. Common Stock | — | — | B | $26.49 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases with limited treatment options. The company leverages its proprietary EXACT platform, which enables precise control of transgene expression to overcome disease-causing genetic mutations. Its pipeline includes NGN-401 for Rett syndrome and NGN-101, an AAV9-delivered gene therapy for CLN5 Batten disease.